Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...

Clinical Trials

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera

Completed

Conditions: Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Dimethyl fumarate

First Posted Date: 2021-02-16

Last Posted Date: 2023-10-23

Lead Sponsor: Biogen

Target Recruit Count: 1507

Registration Number: NCT04756687

Locations: 🇫🇷
Research Site, Île-de-France - Salpêtrière, France

Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Diagnostic Test: DigiCog (BCCAMS app)
Diagnostic Test: Konectom Application

First Posted Date: 2021-02-16

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 158

Registration Number: NCT04756700

Locations: 🇫🇷
Research Site, Bordeaux, France

A Study to Assess Choroideremia (CHM) Health Outcomes

Completed

Conditions: Choroideremia

Interventions: Other: No Intervention

First Posted Date: 2021-02-11

Last Posted Date: 2021-10-14

Lead Sponsor: Biogen

Target Recruit Count: 46

Registration Number: NCT04750785

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Study of Diroximel Fumarate in the Real-World Setting

Terminated

Conditions: Relapsing Forms of MS

Interventions: Drug: Diroximel Fumarate

First Posted Date: 2021-02-10

Last Posted Date: 2023-05-26

Lead Sponsor: Biogen

Target Recruit Count: 75

Registration Number: NCT04746976

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
MS Center at St Barnabas, Livingston, New Jersey, United States
🇺🇸
Memorial Healthcare, Owosso, Michigan, United States

and more 15 locations

Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen

Phase 3

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: Nusinersen

First Posted Date: 2021-01-29

Last Posted Date: 2024-08-21

Lead Sponsor: Biogen

Target Recruit Count: 145

Registration Number: NCT04729907

Locations: 🇨🇴
Hospital Universitario San Ignacio, Bogota, Colombia
🇲🇽
Hospital Infantil de Mexico Federico Gomez, Mexico, Distrito Federal, Mexico
🇷🇺
Russian Children Neuromuscular Center of Veltischev, Moskva, Russian Federation

and more 35 locations

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Completed

Conditions: Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Interferon Beta Therapy

First Posted Date: 2020-12-07

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 470

Registration Number: NCT04655222

Locations: 🇩🇪
Research Site, Göttingen, Germany

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BIIB107
Drug: Placebo

First Posted Date: 2020-10-19

Last Posted Date: 2024-04-15

Lead Sponsor: Biogen

Target Recruit Count: 84

Registration Number: NCT04593121

Locations: 🇺🇸
CenExel Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Altasciences Clinical Research, Overland Park, Kansas, United States
🇺🇸
QPS MRA (Miami Research Associates), Miami, Florida, United States

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BIIB133 (Dapirolizumab pegol)
Drug: Placebo

First Posted Date: 2020-10-01

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 33

Registration Number: NCT04571424

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

Study of BIIB091 Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BIIB091
Drug: Rabeprazole
Drug: Itraconazole

First Posted Date: 2020-09-25

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 59

Registration Number: NCT04564612

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Phase 1

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: BIIB105

First Posted Date: 2020-07-31

Last Posted Date: 2023-10-05

Lead Sponsor: Biogen

Target Recruit Count: 99

Registration Number: NCT04494256

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

and more 14 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy